Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.41 |
| ▸ | HTR2C | P28335 | 12/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899748 | 0.90 | DPP4 (0.36) | — | |
| SCHEMBL5899791 | 0.87 | TRPA1 (0.40) | HTR2AHTR2CMAOBIDO1AGXT | |
| SCHEMBL5899659 | 0.84 | TAAR1 (0.44) | MAOB | |
| SCHEMBL5899598 | 0.81 | TAAR1 (0.40) | MAOB | |
| SCHEMBL5899805 | 0.80 | FFAR4 (0.36) | MAOBGRIN2B | |
| SCHEMBL5899766 | 0.80 | TAAR1 (0.45) | MAOB | |
| SCHEMBL5899751 | 0.79 | DPP4 (0.37) | — | |
| SCHEMBL5899599 | 0.79 | FFAR4 (0.33) | — | |
| SCHEMBL5899760 | 0.77 | TAAR1 (0.34) | MAOBGRIN2B | |
| SCHEMBL5899802 | 0.74 | SLC1A2 (0.42) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030267-B2 | Cycloproply β-amino acid derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1592661-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004065361-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | SCHWARZ JACOB BRADLEY (US) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | CACNA1S, CACNA1D, CACNA1B | HTR2A 235/4885HTR2C 285/4885KCNH2 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.